Pharmaceutical

My Compounding Pharmacy Expands to Offer Veterinary Services Across Australia

My Compounding Pharmacy Expands to Offer Veterinary Services Across Australia SYDNEY CENTRAL BUSINESS DISTRICT, AUSTRALIA / ACCESSWIRE / November 15,…

2 months ago

PreveCeutical Announces Closing of BioGene Therapeutics Transaction

Vancouver, British Columbia--(Newsfile Corp. - November 15, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or…

2 months ago

Perspectum Awarded New FDA Grant to Evaluate Biomarker for Rare Disease Drug Development

WASHINGTON--(BUSINESS WIRE)--#CALiD--Perspectum, a leader in medical imaging quantification techniques, today announced that it has been awarded a 2024 U.S. Food…

2 months ago

Neurophet Appoints CTO Donghyeon Kim as Co-CEO, Joining Jake Junkil Been in Dual Leadership to Drive Global Growth

- Donghyeon Kim, Co-Founder and CTO of Neurophet, to Take On Dual Role as CEO, Heading Technology and Company Leadership…

2 months ago

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders’ Equity Up 8.8% to $35M

Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.Solid liquidity position, with cash…

2 months ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company…

2 months ago

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated…

2 months ago

Theralase(R) Closes Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / November 15, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

2 months ago

Samsung Bioepis Receives Positive CHMP Opinion for Denosumab Biosimilars, OBODENCE™ and XBRYK™

OBODENCE™ and XBRYK™ recommended for approval by the European Medicines Agency for all indications referencing Prolia and Xgeva, respectivelyINCHEON, South…

2 months ago